Last Updated: November 16, 2026

Vivus Llc Company Profile

« Back to Dashboard


Biologic Drugs for Vivus Llc

Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Vivus Llc PANCREAZE pancrelipase Capsule, Delayed Release 022523 10,029,015 2035-05-08 Patent claims search
Vivus Llc PANCREAZE pancrelipase Capsule, Delayed Release 022523 10,040,783 2036-11-30 Patent claims search
Vivus Llc PANCREAZE pancrelipase Capsule, Delayed Release 022523 10,087,493 2029-03-09 Patent claims search
Vivus Llc PANCREAZE pancrelipase Capsule, Delayed Release 022523 10,184,121 2035-06-19 Patent claims search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

Vivus LLC Competitive Landscape Analysis: Market Position, Patent Estate, Products, and Strategic Outlook

Last updated: September 2, 2026

Vivus LLC is a privately held specialty pharmaceutical company with commercial exposure to obesity, erectile dysfunction, and pancreatic enzyme replacement. Its core assets are Qsymia, a once-daily extended-release combination of phentermine and topiramate for chronic weight management; Stendra, an avanafil-based erectile dysfunction treatment; and PANCREAZE, a pancrelipase product. Vivus has a mature product portfolio, limited pipeline visibility, and greater strategic value in established commercial assets, licensing rights, and regulatory infrastructure than in late-stage innovation.

Qsymia remains the company’s most strategically important asset because obesity is a large and expanding market. Its competitive position is constrained by newer GLP-1 and GIP/GLP-1 therapies, including Wegovy, Zepbound, and Saxenda, which have stronger efficacy profiles and substantially greater commercial momentum. The immediate patent question is generic entry for phentermine/topiramate extended-release, while the longer-term issue is whether Vivus can maintain reimbursement and physician demand against injectable incretin therapies.

What products and therapeutic areas does Vivus LLC commercialize?

Vivus has focused on three principal commercial products.

Product Active ingredient Therapeutic area Dosage form Strategic role
Qsymia Phentermine/topiramate extended-release Chronic weight management Oral extended-release capsule Core obesity asset
Stendra Avanafil Erectile dysfunction Oral tablet Licensed or partnered sexual-health asset
PANCREAZE Pancrelipase Exocrine pancreatic insufficiency Delayed-release capsule Mature specialty product

Qsymia was approved by the U.S. Food and Drug Administration in July 2012 for chronic weight management in adults with an initial body-mass index of at least 30 kg/m², or at least 27 kg/m² with a weight-related comorbidity. The approval included a Risk Evaluation and Mitigation Strategy because of topiramate-associated fetal risk and other safety considerations (U.S. Food and Drug Administration [FDA], 2012).

Stendra was approved in April 2012 for erectile dysfunction. The product competes with Viagra, Cialis, Levitra and their generic equivalents. Its commercial differentiation is based primarily on rapid onset and avanafil pharmacology, but the category has experienced substantial price erosion following generic sildenafil and tadalafil entry (FDA, 2012b).

PANCREAZE is a pancreatic enzyme replacement therapy. Its market is specialist-driven and prescription-based, with competition from Creon, Zenpep and other pancrelipase products. Unlike Qsymia, PANCREAZE does not depend on a large consumer-facing market or broad primary-care adoption.

How strong is the Vivus patent estate?

Vivus has a moderate but aging patent estate. Qsymia has the strongest commercial patent position because protection covers the combination, extended-release formulation and methods of treating obesity. Stendra has a smaller and more mature patent position, with core composition and use patents approaching or reaching expiration depending on the specific claim and jurisdiction.

Qsymia patent protection

Public patent records identify several U.S. patents associated with the phentermine/topiramate product and its use. Key patent families include:

Patent General subject matter Strategic relevance
U.S. Patent No. 7,056,890 Phentermine/topiramate combination and related treatment concepts Foundational Qsymia protection
U.S. Patent No. 8,486,960 Obesity treatment and dosing-related claims Method-of-use protection
U.S. Patent No. 8,557,838 Extended-release formulation or dosing claims Formulation and regimen protection

Patent scope must be assessed claim by claim. A patent number alone does not establish that every claim remains enforceable, listed in the Orange Book, or applies to every generic product. Terminal disclaimers, patent-term adjustment, pediatric exclusivity and litigation settlements can alter effective market-entry dates.

Qsymia’s estate is stronger than a single composition patent because it combines product, formulation and method-of-use concepts. Its weakness is timing. Core U.S. protection is mature, and generic applicants have commercial incentives to challenge the product as obesity treatment volumes grow.

Stendra patent protection

Stendra’s active ingredient is avanafil. The patent estate has included U.S. patents covering avanafil, pharmaceutical compositions, and methods of treating erectile dysfunction. The principal commercial issue is that the product entered a category with established generic competition and limited payer tolerance for premium pricing.

Stendra’s patent value is lower than Qsymia’s for three reasons:

  1. Erectile dysfunction has multiple well-established oral therapies.
  2. Generic sildenafil and tadalafil have reset pricing expectations.
  3. Avanafil does not have the market exclusivity profile of a first-in-class therapy.

The asset can remain commercially useful through brand loyalty, physician familiarity, contracting, and geographic licensing, but patent protection alone is unlikely to support high margins after broad generic competition.

PANCREAZE patent and regulatory protection

PANCREAZE is a biologically derived enzyme product rather than a conventional new chemical entity. Its protection depends more heavily on formulation, manufacturing controls, regulatory requirements and product-specific approval standards than on a single broad molecular patent.

Pancrelipase products are difficult to characterize using the same framework applied to small-molecule tablets. Product quality, enzyme activity, delayed-release behavior and manufacturing consistency create technical barriers. These barriers can slow competition, but they do not create indefinite exclusivity.

When does Qsymia lose exclusivity?

Qsymia’s effective loss of exclusivity depends on the patent claims challenged, FDA approval timing, litigation outcomes and any settlement restrictions. The foundational Qsymia patent estate includes patents with expiration dates extending into the mid-to-late 2020s and, for certain claims, potentially later based on patent-term adjustments or specific patent families.

The most relevant commercial window is the period beginning when ANDA applicants can obtain approval and launch without violating enforceable claims. A generic applicant may receive FDA approval before launch is legally permitted if a listed patent remains subject to a 30-month stay or settlement restriction.

Exclusivity factor Qsymia impact
New chemical entity exclusivity Expired; Qsymia was approved in 2012
Five-year NCE protection Not applicable to the combination in the same manner as a new molecular entity
Orange Book patents Product, formulation and method-of-use patents may be listed
Paragraph IV risk High for a mature, commercially relevant obesity product
Pediatric exclusivity Must be evaluated against the specific listed patent
Generic launch timing Depends on ANDA approval, litigation and settlement terms
Biosimilar exposure None; Qsymia is a small-molecule combination product

A generic launch could occur in several stages. The first may involve a limited authorized-generic or settlement launch. A later stage could include multiple ANDA-approved competitors, rapid price compression and reduced pharmacy benefit manager leverage for the branded product.

What is the Orange Book status of Qsymia and Stendra?

The Orange Book is the principal FDA reference for approved drug products and listed patents that may trigger Paragraph IV litigation. Qsymia’s listed patents are commercially important because an ANDA applicant must address each applicable patent through a Paragraph I, II, III or IV certification.

Qsymia’s listing profile is more significant than Stendra’s because Qsymia has a differentiated extended-release combination and a growing therapeutic market. Stendra’s Orange Book value is more limited because the erectile dysfunction market already contains multiple generic alternatives.

An Orange Book listing does not guarantee a patent’s validity. It creates a statutory framework for notice, litigation and a potential 30-month stay. The practical value of a listed patent depends on claim breadth, infringement exposure, prosecution history and the ability to obtain a preliminary injunction or favorable settlement.

Which companies are challenging Vivus products?

Generic competition is most material for Qsymia. Potential or actual ANDA challengers may include large generic manufacturers such as Teva, Amneal, and other companies with experience in complex oral dosage forms. The identity and status of each challenger should be confirmed through current FDA ANDA records, litigation dockets and Vivus or licensee disclosures.

For Stendra, the principal competitive threat is not a single patent challenger. It is the broader generic erectile dysfunction market, particularly sildenafil and tadalafil. Avanafil must compete against low-cost alternatives with extensive physician and patient recognition.

PANCREAZE competes against enzyme replacement products from AbbVie’s Creon franchise, Nestlé’s Zenpep business and other pancrelipase suppliers. Competition is shaped by prescription continuity, specialty pharmacy distribution, product availability and payer formulary placement.

What patent litigation affects Vivus and Qsymia?

Qsymia’s commercial history has included patent disputes involving ANDA applicants. The central litigation question in each case is whether the proposed generic product would infringe valid claims covering the phentermine/topiramate combination, extended-release profile, dosing regimen or obesity treatment method.

Litigation outcomes can produce four materially different results:

Outcome Commercial consequence
Vivus wins on all asserted claims Generic launch may be delayed until patent expiry
Generic wins on invalidity Earlier unrestricted competition is possible
Generic wins on noninfringement A designed-around product may launch
Settlement Entry date, volume limits or licensing terms may govern competition

Settlement agreements require separate antitrust and FTC analysis. A patent settlement that delays entry can preserve revenue but also expose the parties to scrutiny if the arrangement includes reverse-payment economics or restrictions beyond the patent’s likely exclusionary scope.

Publicly available information does not establish a single universal Qsymia entry date for every generic manufacturer. Launch timing can differ by applicant, dosage strength, litigation result and settlement terms.

How does Vivus compare with competing obesity companies?

Vivus occupies a secondary position in obesity pharmacotherapy. Qsymia has an oral route, established FDA approval and meaningful weight-loss efficacy. Its disadvantages are safety monitoring, pregnancy restrictions, controlled-substance handling for phentermine and lower efficacy than leading incretin therapies.

Company or product Modality Competitive advantage Limitation versus Qsymia
Novo Nordisk, Wegovy Injectable semaglutide High demand and strong efficacy Injection, supply and reimbursement constraints
Eli Lilly, Zepbound Injectable tirzepatide Strong clinical efficacy and market momentum Injection and access barriers
Vivus, Qsymia Oral phentermine/topiramate ER Oral dosing, established approval, lower acquisition cost Mature patents and lower efficacy than newer agents
Novo Nordisk, Saxenda Injectable liraglutide Established obesity indication Daily injection and older product profile
Contrave Oral naltrexone/bupropion Oral administration Different tolerability and efficacy profile
Orlistat products Oral lipase inhibition Low cost and broad availability Gastrointestinal tolerability

The strategic pressure on Qsymia is commercial rather than purely legal. Even if patent protection delays generic entry, physicians and payers may favor GLP-1-based treatments for patients seeking larger weight reductions or broader metabolic benefits.

What strengths does Vivus have?

Vivus has five material strengths.

Established FDA-approved products

The company has products with known prescribing information, safety databases, distribution channels and reimbursement histories. This lowers development risk compared with a pre-revenue biotechnology company.

Oral obesity positioning

Qsymia is an oral alternative in a market dominated by injectable products. Patients who prefer oral administration, cannot tolerate injections or face coverage restrictions may remain accessible targets.

Combination-product know-how

Qsymia’s value includes formulation and dosing expertise. Extended-release delivery of two active ingredients creates technical and regulatory requirements that can be more complex than a conventional immediate-release generic.

Specialty-commercial infrastructure

The products address specialist and primary-care markets where targeted commercial execution can support revenue without the cost structure of a large diversified pharmaceutical company.

Licensing optionality

Vivus has used licensing and commercialization arrangements for assets such as Stendra. Licensing can monetize a product in territories where the company lacks an efficient sales organization.

What weaknesses and risks affect Vivus LLC?

Vivus has several structural weaknesses.

First, the portfolio is concentrated. Qsymia represents the main growth opportunity, while Stendra and PANCREAZE operate in mature or highly competitive categories.

Second, the patent estate is aging. Patent expiry and Paragraph IV challenges can reduce revenue quickly because oral products are susceptible to price erosion once several generics enter.

Third, the company lacks the scale of Novo Nordisk, Eli Lilly, AbbVie or large generic manufacturers. Scale affects payer contracting, patient-support programs, supply-chain resilience and litigation budgets.

Fourth, Qsymia faces clinical and commercial competition from therapies with stronger average weight-loss outcomes. The product’s controlled-substance component and topiramate-related safety restrictions can also complicate prescribing.

Fifth, Vivus is private, so public disclosure of revenue, cash flow, product-level profitability, patent strategy and litigation reserves is more limited than for a publicly traded pharmaceutical company.

What generic launch scenarios exist for Qsymia?

The likely scenarios fall into three categories.

Delayed generic entry

Vivus or its commercial partner preserves enforceable patent claims through litigation or settlement. Generic launch occurs after a negotiated date, potentially with a limited number of entrants.

Single or limited generic entry

One applicant launches under a settlement or after prevailing in litigation. Price erosion occurs, but the branded product retains some formulary access and physician recognition.

Broad generic entry

Multiple ANDA applicants launch after patent expiry or invalidation. Pharmacy benefit managers shift volume to generics, branded net pricing falls, and Qsymia revenue becomes dependent on adherence, residual brand preference and limited-distribution economics.

The third scenario is the most damaging to a concentrated company because Qsymia is both the most valuable asset and the product most exposed to obesity-market substitution.

What licensing deals affect Vivus products?

Vivus has historically relied on commercial partnerships rather than building a global sales infrastructure for every asset. Stendra’s commercialization has involved external partners, including U.S. rights arrangements associated with Auxilium and later commercial ownership changes involving Endo and Metuchen.

The strategic value of these deals depends on:

  • Territory covered
  • Remaining patent life
  • Royalty rate and minimum payments
  • Manufacturing responsibility
  • Promotional obligations
  • Termination rights
  • Change-of-control provisions
  • Liability for regulatory and product claims

Licensing can reduce operating costs, but it also limits direct control over pricing, promotion and launch timing. For a mature product, a licensing partner may prioritize cash generation over investment in market expansion.

What is the FDA regulatory status of Vivus products?

Qsymia, Stendra and PANCREAZE have FDA approval for their respective indications. Qsymia’s approval includes significant prescribing and risk-management conditions, including contraindications and warnings related to pregnancy and topiramate exposure. Stendra is approved for erectile dysfunction, while PANCREAZE is approved for exocrine pancreatic insufficiency associated with cystic fibrosis and other conditions requiring pancreatic enzyme replacement.

None of these assets is a biosimilar. Biosimilar risk is therefore not a direct competitive issue. The relevant FDA pathways are:

  • ANDA approval for generic small-molecule versions of Qsymia or Stendra
  • Product-specific or complex-generic pathways for pancrelipase
  • Supplemental applications for labeling, strength or formulation changes
  • Postmarketing safety requirements and manufacturing compliance

How broad is Vivus’s geographic coverage?

Vivus’s strongest regulatory and commercial relevance has been in the United States. International rights have generally depended on local approvals, licensees and distribution partners. Patent protection is jurisdiction-specific, and U.S. patent expiry does not determine entry timing in Europe, Canada, Japan or other markets.

Geographic analysis should distinguish among:

  1. Patent coverage.
  2. Marketing authorization.
  3. Commercial rights.
  4. Manufacturing rights.
  5. Actual sales and reimbursement access.

A product may have regulatory approval in a jurisdiction but no active commercial partner. It may also have a licensee with marketing rights but no meaningful patent protection.

What manufacturing and intellectual-property barriers protect Vivus products?

Qsymia’s manufacturing barriers are moderate. The product requires controlled release of two active ingredients, consistent dose uniformity and compliance with applicable requirements for phentermine handling. These factors may complicate development but are unlikely to block well-capitalized generic manufacturers indefinitely.

PANCREAZE has higher technical barriers because pancrelipase products require control of enzyme activity, source material, enteric protection, stability and batch consistency. Manufacturing execution and regulatory documentation are important competitive assets.

Stendra’s manufacturing barriers are comparatively low once core active-ingredient and formulation patents expire. Avanafil synthesis and tablet manufacturing are within the capabilities of established generic producers.

How should investors and licensors assess Vivus’s revenue exposure?

Revenue exposure is concentrated in Qsymia and should be modeled against three variables:

Variable Downside indicator Upside indicator
Qsymia net sales Generic approval or broad formulary substitution Sustained oral obesity demand
Patent life Invalidity or noninfringement ruling Enforceable formulation or use claims
Market access GLP-1 preference and reimbursement pressure Coverage restrictions on injectable therapies
Stendra revenue Generic PDE5 competition Partner-led niche positioning
PANCREAZE revenue Competitor supply and payer substitution Manufacturing reliability and specialty retention

The most important valuation question is not whether Vivus has approved products. It is whether those products can produce durable cash flow after patent expiry and amid therapeutic substitution.

Key Takeaways

  • Vivus LLC is a specialty pharmaceutical company with a concentrated portfolio led by Qsymia.
  • Qsymia has the strongest strategic value because it participates in the obesity market and has oral dosing.
  • Qsymia’s patent estate includes combination, formulation and method-of-use protection, but the estate is mature and exposed to Paragraph IV challenges.
  • Stendra competes in a heavily commoditized erectile dysfunction market and has lower strategic value than Qsymia.
  • PANCREAZE has greater manufacturing and regulatory complexity than conventional tablets, but pancrelipase competition remains established.
  • Vivus has no biosimilar exposure because its principal products are not biologics.
  • The primary commercial threat is the combination of generic entry and substitution by GLP-1 and GIP/GLP-1 therapies.
  • Vivus’s private-company status limits public visibility into product-level revenue, litigation reserves and licensing economics.
  • The most important diligence items are current Orange Book listings, ANDA litigation, settlement terms, patent expiration calculations and Qsymia reimbursement trends.

FAQs About Vivus LLC’s Competitive Position

Is Qsymia a biologic or a small-molecule drug?

Qsymia is a small-molecule combination product containing phentermine and topiramate in an extended-release oral capsule. It is subject to generic-drug, not biosimilar, competition.

Does Vivus still have market exclusivity for Qsymia?

Qsymia’s original FDA exclusivity has expired. Commercial exclusivity depends on the remaining enforceable patents, Orange Book listings, litigation outcomes and any generic settlement agreements.

What is the main competitor to Qsymia?

The strongest commercial competitors are Wegovy and Zepbound. Contrave and Saxenda also compete in prescription obesity treatment, while generic phentermine and other low-cost therapies compete on price.

Can a generic company copy Qsymia’s extended-release profile?

A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway and address listed patents. A formulation that avoids specific patent claims may launch earlier than a product that infringes them.

Is Vivus LLC publicly traded?

Vivus LLC is a private company rather than a publicly traded issuer. It therefore provides less routine financial and pipeline disclosure than companies such as Novo Nordisk, Eli Lilly or AbbVie.

References

  1. U.S. Food and Drug Administration. (2012a). FDA approves weight-management drug Qsymia. https://www.fda.gov
  2. U.S. Food and Drug Administration. (2012b). FDA approves Stendra for erectile dysfunction. https://www.fda.gov
  3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
  4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
  5. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
  6. Vivus LLC. (n.d.). Qsymia prescribing information.
  7. Vivus LLC. (n.d.). Stendra prescribing information.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.